Primary medical therapy for acromegaly (Q35086868)

6 August 2017

1 reference

title

Primary medical therapy for acromegaly (English)

1 reference

6 August 2017

Michael C Sheppard

1

1 reference

6 August 2017

publication date

1 April 2003

1 reference

6 August 2017

published in

Clinical Endocrinology

1 reference

6 August 2017

volume

58

1 reference

6 August 2017

issue

4

1 reference

6 August 2017

page(s)

387-399

1 reference

Transsphenoidal microsurgery for growth hormone-secreting pituitary adenomas: initial outcome and long-term results

6 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1046/J.1365-2265.2003.01734.X

Outcome of transphenoidal surgery for acromegaly and its relationship to surgical experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1046/J.1365-2265.2003.01734.X

Primary medical therapy for acromegaly: an open, prospective, multicenter study of the effects of subcutaneous and intramuscular slow-release octreotide on growth hormone, insulin-like growth factor-I, and tumor size

21 January 2018

1 reference

https://api.crossref.org/works/10.1046/J.1365-2265.2003.01734.X

Efficacy and tolerability of the long-acting somatostatin analog lanreotide in acromegaly. A 12-month multicenter study of 58 acromegalic patients. French Multicenter Study Group on Lanreotide in Acromegaly.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046/J.1365-2265.2003.01734.X

Growth hormone and the heart

21 January 2018

1 reference

https://api.crossref.org/works/10.1046/J.1365-2265.2003.01734.X

Lanreotide 60 mg, a longer-acting somatostatin analog: tumor shrinkage and hormonal normalization in acromegaly.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046/J.1365-2265.2003.01734.X

Long‐term therapy with long‐acting octreotide (Sandostatin‐LAR®) for the management of acromegaly

21 January 2018

1 reference

https://api.crossref.org/works/10.1046/J.1365-2265.2003.01734.X

Outcome of surgery for acromegaly--the experience of a dedicated pituitary surgeon

21 January 2018

1 reference

https://api.crossref.org/works/10.1046/J.1365-2265.2003.01734.X

Effectiveness and tolerability of slow release lanreotide treatment in active acromegaly: six-month report on an Italian multicenter study. Italian Multicenter Slow Release Lanreotide Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046/J.1365-2265.2003.01734.X

Criteria for cure of acromegaly: a consensus statement

21 January 2018

1 reference

https://api.crossref.org/works/10.1046/J.1365-2265.2003.01734.X

Epidemiology of acromegaly

21 January 2018

1 reference

https://api.crossref.org/works/10.1046/J.1365-2265.2003.01734.X

Results of a European multicentre study with Sandostatin LAR in acromegalic patients. Sandostatin LAR Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046/J.1365-2265.2003.01734.X

The outcome of surgery for acromegaly: the need for a specialist pituitary surgeon for all types of growth hormone (GH) secreting adenoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1046/J.1365-2265.2003.01734.X

Echocardiographic evidence for a direct effect of GH/IGF-I hypersecretion on cardiac mass and function in young acromegalics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046/J.1365-2265.2003.01734.X

Octreotide as Primary Therapy for Acromegaly1

21 January 2018

1 reference

https://api.crossref.org/works/10.1046/J.1365-2265.2003.01734.X

Mortality and cancer incidence in acromegaly: a retrospective cohort study. United Kingdom Acromegaly Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046/J.1365-2265.2003.01734.X

Outcome of transsphenoidal surgery for acromegaly using strict criteria for surgical cure

21 January 2018

1 reference

https://api.crossref.org/works/10.1046/J.1365-2265.2003.01734.X

Current therapy for acromegaly

21 January 2018

1 reference

https://api.crossref.org/works/10.1046/J.1365-2265.2003.01734.X

Clinical and biochemical response following withdrawal of a long-acting, depot injection form of octreotide (Sandostatin-LAR).

21 January 2018

1 reference

https://api.crossref.org/works/10.1046/J.1365-2265.2003.01734.X

Long-term mortality after transsphenoidal surgery and adjunctive therapy for acromegaly

21 January 2018

1 reference

https://api.crossref.org/works/10.1046/J.1365-2265.2003.01734.X

Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1046/J.1365-2265.2003.01734.X

Long-term treatment of 189 acromegalic patients with the somatostatin analog octreotide. Results of the International Multicenter Acromegaly Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046/J.1365-2265.2003.01734.X

Growth hormone: its measurement and the need for assay harmonization

21 January 2018

1 reference

https://api.crossref.org/works/10.1046/J.1365-2265.2003.01734.X

Two-Year Follow-Up of Acromegalic Patients Treated with Slow Release Lanreotide (30 mg)

21 January 2018

1 reference

https://api.crossref.org/works/10.1046/J.1365-2265.2003.01734.X

How many surgeons to operate on acromegalic patients?

21 January 2018

1 reference

https://api.crossref.org/works/10.1046/J.1365-2265.2003.01734.X

Octreotide treatment of acromegaly. A randomized, multicenter study

21 January 2018

1 reference

https://api.crossref.org/works/10.1046/J.1365-2265.2003.01734.X

Place of pegvisomant in acromegaly

21 January 2018

1 reference

https://api.crossref.org/works/10.1046/J.1365-2265.2003.01734.X

Acromegaly, colonic polyps and carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1046/J.1365-2265.2003.01734.X

Acromegaly and cardiovascular disorders. A prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1046/J.1365-2265.2003.01734.X

Long-term treatment of acromegaly with the somatostatin analogue SR-lanreotide

21 January 2018

1 reference

https://api.crossref.org/works/10.1046/J.1365-2265.2003.01734.X

Treatment of Acromegaly with the Growth Hormone–Receptor Antagonist Pegvisomant

21 January 2018

1 reference

https://api.crossref.org/works/10.1046/J.1365-2265.2003.01734.X

Modern approaches to treating acromegaly

21 January 2018

1 reference

https://api.crossref.org/works/10.1046/J.1365-2265.2003.01734.X

21 January 2018

Treatment of acromegaly

1 reference

https://api.crossref.org/works/10.1046/J.1365-2265.2003.01734.X

Retrospective analysis of long-term surgical results in acromegaly: preoperative and postoperative factors predicting outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1046/J.1365-2265.2003.01734.X

10.1046/J.1365-2265.2003.01734.X

21 January 2018

Identifiers

DOI

1 reference

6 August 2017

1 reference